SORRENTO THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • April 1st, 2014 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
This Employment Agreement (this “Agreement”), effective as of December 19, 2013 (the “Effective Date”), is made by and between Sorrento Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Zhenwei (or “David”) Miao (the “Executive”) (collectively referred to herein as the “Parties”).
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENTLoan and Security Agreement • April 1st, 2014 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research
THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of March 31, 2014 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and SORRENTO THERAPEUTICS, INC., a Delaware corporation (“Parent”), IGDRASOL, INC., a Delaware corporation (“IgDraSol”), and SHERRINGTON PHARMACEUTICALS, INC., a Delaware corporation (“Sherrington”), each with offices located at 6042 Cornerstone Court, Suite B,
